{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ghosh S"],"funding":["Indian Council of Medical Research","Indian Council of Medical Research (ICMR)"],"pagination":["e0402623"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11237457"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(6)"],"pubmed_abstract":["Post-kala-azar dermal leishmaniasis (PKDL) patients are a key source of <i>Leishmania donovani</i> parasites, hindering the goal of eliminating visceral leishmaniasis (VL). Monitoring treatment response and parasite susceptibility is essential due to increasing drug resistance. We assessed the drug susceptibility of PKDL isolates (<i>n</i> = 18) from pre-miltefosine (MIL) era (1997-2004) with isolates (<i>n</i> = 16) from the post-miltefosine era (2010-2019) and post-miltefosine treatment relapse isolates (<i>n</i> = 5) towards miltefosine and amphotericin B (AmB) at promastigote stage and towards sodium antimony gluconate (SAG) at amastigote stage. PKDL isolates were examined for mutation in gene-encoding AQP1 transporter, C26882T mutation on chromosome 24, and miltefosine-transporter (MT"],"journal":["Microbiology spectrum"],"pubmed_title":["Antimony susceptible <i>Leishmania donovani</i>: evidence from <i>in vitro</i> drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era."],"pmcid":["PMC11237457"],"funding_grant_id":["6/9-7(188)2018-ECDII"],"pubmed_authors":["Kumar D","Ramesh V","Ghosh S","Verma A","Salotra P","Deep DK","Singh R"],"additional_accession":[]},"is_claimable":false,"name":"Antimony susceptible <i>Leishmania donovani</i>: evidence from <i>in vitro</i> drug susceptibility of parasites isolated from patients of post-kala-azar dermal leishmaniasis in pre- and post-miltefosine era.","description":"Post-kala-azar dermal leishmaniasis (PKDL) patients are a key source of <i>Leishmania donovani</i> parasites, hindering the goal of eliminating visceral leishmaniasis (VL). Monitoring treatment response and parasite susceptibility is essential due to increasing drug resistance. We assessed the drug susceptibility of PKDL isolates (<i>n</i> = 18) from pre-miltefosine (MIL) era (1997-2004) with isolates (<i>n</i> = 16) from the post-miltefosine era (2010-2019) and post-miltefosine treatment relapse isolates (<i>n</i> = 5) towards miltefosine and amphotericin B (AmB) at promastigote stage and towards sodium antimony gluconate (SAG) at amastigote stage. PKDL isolates were examined for mutation in gene-encoding AQP1 transporter, C26882T mutation on chromosome 24, and miltefosine-transporter (MT","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2025-06-01T02:33:14.555Z","creation":"2025-06-01T02:33:14.555Z"},"accession":"S-EPMC11237457","cross_references":{"pubmed":["38712926"],"doi":["10.1128/spectrum.04026-23"]}}